SCHEMBL7052115

SCHEMBL7052115

CCOC(=O)C(CCc1ccccc1)(C[PH](=O)CSc1cccc2ccccc12)OCC

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.34
ALDH1A1 P00352 4/20 0.33
HPGD P15428 3/20 0.33
CDC25B P30305 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TAAR1 Q96RJ0 2/20 0.32
THRB P10828 1/20 0.32
KDM4E B2RXH2 1/20 0.32
TP53 P04637 1/20 0.32
HTT P42858 1/20 0.32
HSD17B10 Q99714 1/20 0.32
RECQL P46063 1/20 0.32
MMP8 P22894 1/20 0.32
MAPT P10636 2/20 0.32
PRNP P04156 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GPR52 Q9Y2T5 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052130 0.94 ALDH1A1 (0.33) LMNAALDH1A1HPGDCDC25BMEN1
SCHEMBL7051265 0.90 ALDH1A1 (0.38) LMNAALDH1A1HPGDCDC25BMEN1
SCHEMBL7049848 0.85 ALDH1A1 (0.36) LMNAALDH1A1HPGDMEN1KMT2A
SCHEMBL7050190 0.85 ALDH1A1 (0.35) LMNAALDH1A1HPGDCDC25BMEN1
SCHEMBL7049141 0.84 ALDH1A1 (0.34) LMNAALDH1A1HPGDTAAR1THRB
SCHEMBL7054025 0.83 ALDH1A1 (0.34) LMNAALDH1A1HPGDCDC25BMEN1
SCHEMBL7051087 0.81 PRNP (0.47) LMNAALDH1A1MEN1KMT2ATHRB
SCHEMBL7049813 0.79 ALDH1A1 (0.40) LMNAALDH1A1MEN1KMT2ATAAR1
SCHEMBL7047044 0.79 ALDH1A1 (0.35) LMNAALDH1A1HPGDMEN1KMT2A
SCHEMBL7051097 0.79 ALDH1A1 (0.35) LMNAALDH1A1KMT2ATAAR1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 LMNA 488/4885ALDH1A1 465/4885HPGD 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.